131-I-Metaiodobenzylguanidine Treatment in Patients with Refractory Advanced Neuroblastoma

Authors:
  • JSJ. C. Sisson
    J. C. Sisson
  • BSB. Shapiro
    B. Shapiro
  • JMJ. S. Miser
    J. S. Miser
  • DND. Normole
    D. Normole
  • IFI. R. Francis
    I. R. Francis
  • KZK. Zasadny
    K. Zasadny
  • JCJ. E. Carey
    J. E. Carey
  • JJJ. W. Johnson
    J. W. Johnson
  • MAMallette
    Mallette
  • BMB. Mudgette
    B. Mudgette

Abstract
Fourteen patients with refractory advanced neuroblastoma were treated with 131-I-metaiodobenzylguanidine (131–1-MIBG); all had evidence of progressive disease or recurrent disease following combination chemotherapy. One patient without gross evidence of disease, following surgical resection of recurrent neuroblastoma before therapy with 131-I-MIBG, remains healthy without regrowth of tumor 3.5 years later. Two other patients had minor responses, and one had a mixed response. Two patients remain alive 1,212 and 1,926 days following the initial 131-I-MIBG treatment; the remaining 12 patients died of progressive disease. Moderate myelosuppression was the most notable toxicity observed; mild nausea and vomiting and transient mild liver enzyme elevation were also encountered. Treatment with 131-I-MIBG produced antineoplastic activity in patients with neuroblastoma and was well tolerated. To evaluate dose escalation, alternative dosage schedules, and alternative MIBG-radioconjugates, additional trials of radiolabeled MIBG are indicated.